![](data:image/svg+xml;charset=utf-8,<svg height="32" width="135" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="16" width="68" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="18" width="8" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="15" width="18" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="15" width="15" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="675" width="1200" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
First Published: 21 Feb 2023, 05:55 PM IST
Pharma firms' third quarter numbers remain in line with expectations; Lupin, Divi's Labs see downgrades
Updated: 21 Feb 2023, 05:55 PM IST
TL;DR.
Brokerage firm Motilal Oswal Financial Services observed the December quarter earnings of the pharma companies under its coverage were in line with expectations.
vacccine_1645181775221